PROGRAM CHAIR
Alok Khorana, MD
Professor of Medicine
Hardis Chair in Oncology Research
Cleveland Clinic
Cleveland, OH
PROGRAM OVERVIEW
This Enduring of the TeleECHO Series will help healthcare professionals diagnose, manage, and prevent venous thromboembolism (VTE) in cancer, based on risk stratification, clinical trial data, and appropriate guideline-informed strategies in order to optimize clinical outcomes. This program will inform participants of the latest best practices as recommended by professional guidelines and will equip participants to integrate multidisciplinary care and shared decision-making in practice.
TARGET AUDIENCE
This activity is intended for U.S.-based oncologists, community oncologists, primary care providers, allied healthcare professionals (i.e., NPs, PAs, pharmacists), VTE specialists, and/or other healthcare professionals involved in the care of patients with cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize best practices to facilitate timely diagnosis of cancer-associated VTE
- Assess evidence-based best practices in the prevention and management of cancer-associated VTE
- Justify personalized patient management plans in the prevention and management of cancer-associated VTE
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Alok Khorana, MD | Consultant for Bristol Myers Squibb, Pfizer, Sanofi, Bayer, Anthos, WebMD |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Associate Program Manager, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: April 15, 2024
EXPIRATION DATE: April 15, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
